The genetic basis and expanding role of molecular analysis in the diagnosis, prognosis, and therapeutic design for myelodysplastic syndromes

Journal of Molecular Diagnostics

Volumn 16, Issue 2, 2014, Pages 145-158

  Nybakken, Grant E ^a   Bagg, Adam ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; EPIGENESIS, GENETIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MUTATION; MYELODYSPLASTIC SYNDROMES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS;

EID: 84894032502     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2013.11.005     Document Type: Review

References (84)

1. X. Ma, M. Does, A. Raza, and S.T. Mayne Myelodysplastic syndromes: incidence and survival in the United States Cancer 109 2007 1536 1542
2. Myelodysplastic syndromes S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, and J.W. Vardiman WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues ed 4. 2008 IARC Press Lyon, France 87 108
3. J.M. Bennett, D. Catovsky, M.T. Daniel, G. Flandrin, D.A. Galton, H.R. Gralnick, and C. Sultan Proposals for the classification of the acute leukaemias. French-American-British (FAB) Co-Operative Group Br J Haematol 33 1976 451 458
4. P. Greenberg, C. Cox, M.M. LeBeau, P. Fenaux, P. Morel, G. Sanz, M. Sanz, T. Vallespi, T. Hamblin, D. Oscier, K. Ohyashiki, K. Toyama, C. Aul, G. Mufti, and J. Bennett International scoring system for evaluating prognosis in myelodysplastic syndromes [Erratum appeared in Blood 1998, 91:1100] Blood 89 1997 2079 2088
5. C.D. Watt, M.R. Roullet, and A. Bagg Role of cytogenetic analysis in the diagnosis and classification of hematopoietic neoplasms, ch 9 A. Orazi, D.M. Knowles, K. Foucar, L.M. Weiss, Knowles' Neoplastic Hematopathology ed 3. 2013 Lippincott Williams & Wilkins Philadelphia 000-000
6. A.A. van de Loosdrecht, and T.M. Westers Cutting edge: flow cytometry in myelodysplastic syndromes J Natl Compr Canc Netw 11 2013 892 902
7. H.J. Olney, and M.M. Le Beau Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes Leuk Res 31 2007 427 434
8. D. Haase, U. Germing, J. Schanz, M. Pfeilstöcker, T. Nösslinger, B. Hildebrandt, A. Kundgen, M. Lübbert, R. Kunzmann, A.A. Giagounidis, C. Aul, L. Trümper, O. Krieger, R. Stauder, T.H. Müller, F. Wimazal, P. Valent, C. Fonatsch, and C. Steidl New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients Blood 110 2007 4385 4395
9. J. Schanz, H. Tüchler, F. Solé, M. Mallo, E. Luño, J. Cervera, I. Granada, B. Hildebrandt, M.L. Slovak, K. Ohyashiki, C. Steidl, C. Fonatsch, M. Pfeilstöcker, T. Nösslinger, P. Valent, A. Giagounidis, C. Aul, M. Lübbert, R. Stauder, O. Krieger, G. Garcia-Manero, S. Faderl, S. Pierce, M.M. Le Beau, J.M. Bennett, P. Greenberg, U. Germing, and D. Haase New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge J Clin Oncol 30 2012 820 829
10. L.A. Godley, and R.A. Larson Therapy-related myeloid leukemia Semin Oncol 35 2008 418 429
11. B.L. Ebert, J. Pretz, J. Bosco, C.Y. Chang, P. Tamayo, N. Galili, A. Raza, D.E. Root, E. Attar, S.R. Ellis, and T.R. Golub Identification of RPS14 as a 5q- syndrome gene by RNA interference screen Nature 451 2008 335 339
12. J.L. Barlow, L.F. Drynan, N.L. Trim, W.N. Erber, A.J. Warren, and A.N. McKenzie New insights into 5q- syndrome as a ribosomopathy Cell Cycle 9 2010 4286 4293
13. M.S. Kumar, A. Narla, A. Nonami, A. Mullally, N. Dimitrova, B. Ball, J.R. McAuley, L. Poveromo, J.L. Kutok, N. Galili, A. Raza, E. Attar, D.G. Gilliland, T. Jacks, and B.L. Ebert Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome Blood 118 2011 4666 4673
14. T. Ernst, A.J. Chase, J. Score, C.E. Hidalgo-Curtis, C. Bryant, A.V. Jones, K. Waghorn, K. Zoi, F.M. Ross, A. Reiter, A. Hochhaus, H.G. Drexler, A. Duncombe, F. Cervantes, D. Oscier, J. Boultwood, F.H. Grand, and N.C. Cross Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders Nat Genet 42 2010 722 726
15. A. Jerez, Y. Sugimoto, H. Makishima, A. Verma, A.M. Jankowska, B. Przychodzen, V. Visconte, R.V. Tiu, C.L. O'Keefe, A.M. Mohamedali, A.G. Kulasekararaj, A. Pellagatti, K. McGraw, H. Muramatsu, A.R. Moliterno, M.A. Sekeres, M.A. McDevitt, S. Kojima, A. List, J. Boultwood, G.J. Mufti, and J.P. Maciejewski Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis Blood 119 2012 6109 6117
16. L. Malcovati, U. Germing, A. Kuendgen, M.G. Della Porta, C. Pascutto, R. Invernizzi, A. Giagounidis, B. Hildebrandt, P. Bernasconi, S. Knipp, C. Strupp, M. Lazzarino, C. Aul, and M. Cazzola Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes J Clin Oncol 25 2007 3503 3510
17. J. Schanz, C. Steidl, C. Fonatsch, M. Pfeilstöcker, T. Nösslinger, H. Tuechler, P. Valent, B. Hildebrandt, A. Giagounidis, C. Aul, M. Lübbert, R. Stauder, O. Krieger, G. Garcia-Manero, H. Kantarjian, U. Germing, D. Haase, and E. Estey Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system J Clin Oncol 29 2011 1963 1970
18. P.L. Greenberg, H. Tuechler, J. Schanz, G. Sanz, G. Garcia-Manero, F. Solé, J.M. Bennett, D. Bowen, P. Fenaux, F. Dreyfus, H. Kantarjian, A. Kuendgen, A. Levis, L. Malcovati, M. Cazzola, J. Cermak, C. Fonatsch, M.M. Le Beau, M.L. Slovak, O. Krieger, M. Luebbert, J. Maciejewski, S.M. Magalhaes, Y. Miyazaki, M. Pfeilstöcker, M. Sekeres, W.R. Sperr, R. Stauder, S. Tauro, P. Valent, T. Vallespi, A.A. van de Loosdrecht, U. Germing, and D. Haase Revised International Prognostic Scoring System for myelodysplastic syndromes Blood 120 2012 2454 2465
19. D.A. Breems, W.L. Van Putten, G.E. De Greef, S.L. Van Zelderen-Bhola, K.B. Gerssen-Schoorl, C.H. Mellink, A. Nieuwint, M. Jotterand, A. Hagemeijer, H.B. Beverloo, and B. Löwenberg Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype J Clin Oncol 26 2008 4791 4797
20. M.M. Patnaik, C.A. Hanson, J.M. Hodnefield, R. Knudson, D.L. Van Dyke, and A. Tefferi Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype Leukemia 25 2011 266 270
21. K. Wudhikarn, R. Van Rheeden, C. Leopold, P. Rattanaumpawan, R. Gingrich, and M. de Magalhaes Silverman Outcome of allogeneic stem cell transplantation in myelodysplastic syndrome patients: prognostic implication of monosomal karyotype Eur J Haematol 89 2012 294 301
22. C.B. Belli, R. Bengió, P.N. Aranguren, F. Sakamoto, M.G. Flores, N. Watman, E. Nucifora, M.V. Prates, J. Arbelbide, and I. Larripa Partial and total monosomal karyotypes in myelodysplastic syndromes: comparative prognostic relevance among 421 patients Am J Hematol 86 2011 540 545
23. S. Heim, and F. Mitelman Cancer cytogenetics ed 3. 2009 Wiley-Blackwell Hoboken, NJ
24. J. Schanz, H. Tuchler, F. Solé, M. Mallo, E. Luño, J. Cervera, J. Grau, B. Hildebrandt, M.L. Slovak, K. Ohyashiki, C. Steidl, C. Fonatsch, M. Pfeilstöcker, T. Nösslinger, P. Valent, A. Giagounidis, C. Aul, M. Lubbert, R. Stauder, O. Krieger, M.M. Le Beau, J.M. Bennett, P. Greenberg, U. Germing, and D. Haase Monosomal karyotype in MDS: explaining the poor prognosis? Leukemia 27 2013 1988 1995
25. H. Wang, X.Q. Wang, X.P. Xu, and G.W. Lin Cytogenetic evolution correlates with poor prognosis in myelodysplastic syndrome Cancer Genet Cytogenet 196 2010 159 166
26. T. de Souza Fernandez, M.H. Ornellas, L. Otero de Carvalho, D. Tabak, and E. Abdelhay Chromosomal alterations associated with evolution from myelodysplastic syndrome to acute myeloid leukemia Leuk Res 24 2000 839 848
27. P. Bernasconi, P.M. Cavigliano, M. Boni, S. Calatroni, C. Klersy, I. Giardini, B. Rocca, N. Crosetto, M. Caresana, M. Lazzarino, and C. Bernasconi Is FISH a relevant prognostic tool in myelodysplastic syndromes with a normal chromosome pattern on conventional cytogenetics? A study on 57 patients Leukemia 17 2003 2107 2112
28. M. Romeo, L. Chauffaille Mde, M.R. Silva, D.M. Bahia, and J. Kerbauy Comparison of cytogenetics with FISH in 40 myelodysplastic syndrome patients Leuk Res 26 2002 993 996
29. J.F. Coleman, K.S. Theil, R.R. Tubbs, and J.R. Cook Diagnostic yield of bone marrow and peripheral blood FISH panel testing in clinically suspected myelodysplastic syndromes and/or acute myeloid leukemia: a prospective analysis of 433 cases Am J Clin Pathol 135 2011 915 920
30. H. Jiang, Y. Xue, Q. Wang, J. Pan, Y. Wu, J. Zhang, S. Bai, Q. Wang, G. He, A. Sun, D. Wu, and S. Chen The utility of fluorescence in situ hybridization analysis in diagnosing myelodysplastic syndromes is limited to cases with karyotype failure Leuk Res 36 2012 448 452
31. D. Costa, S. Valera, A. Carrió, A. Arias, C. Muñoz, M. Rozman, M. Belkaid, R. Coutinho, B. Nomdedeu, and E. Campo Do we need to do fluorescence in situ hybridization analysis in myelodysplastic syndromes as often as we do? Leuk Res 34 2010 1437 1441
32. C.W. Pitchford, A.C. Hettinga, and K.K. Reichard Fluorescence in situ hybridization testing for -5/5q, -7/7q, +8, and del(20q) in primary myelodysplastic syndrome correlates with conventional cytogenetics in the setting of an adequate study Am J Clin Pathol 133 2010 260 264
33. W. Yang, B. Stotler, D.W. Sevilla, F.N. Emmons, V.V. Murty, B. Alobeid, and G. Bhagat FISH analysis in addition to G-band karyotyping: utility in evaluation of myelodysplastic syndromes? Leuk Res 34 2010 420 425
34. A.M. Cherry, S.R. Brockman, S.F. Paternoster, G.A. Hicks, D. Neuberg, R.R. Higgins, J.M. Bennett, P.L. Greenberg, K. Miller, M.S. Tallman, J. Rowe, and G.W. Dewald Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study Leuk Res 27 2003 1085 1090
35. N. Douet-Guilbert, A. Herry, M.J. Le Bris, N. Guéganic, C. Bovo, F. Morel, and M. De Braekeleer Interphase FISH does not improve the detection of DEL(5q) and DEL(20q) in myelodysplastic syndromes Anticancer Res 31 2011 1007 1010
36. R.P. Ketterling, W.A. Wyatt, S.A. VanWier, M. Law, J.M. Hodnefield, C.A. Hanson, and G.W. Dewald Primary myelodysplastic syndrome with normal cytogenetics: utility of 'FISH panel testing' and M-FISH Leuk Res 26 2002 235 240
37. G.M. Rigolin, R. Bigoni, R. Milani, F. Cavazzini, M.G. Roberti, A. Bardi, P. Agostini, M. Della Porta, A. Tieghi, N. Piva, A. Cuneo, and G. Castoldi Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype Leukemia 15 2001 1841 1847
38. M. Mallo, L. Arenillas, B. Espinet, M. Salido, J.M. Hernández, and E. Lumbreras et al. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q Haematologica 93 2008 1001 1008
39. L. Wilkens, D. Burkhardt, J. Tchinda, G. Büsche, M. Werner, M. Nolte, A. Ganser, and A. Georgii Cytogenetic aberrations in myelodysplastic syndrome detected by comparative genomic hybridization and fluorescence in situ hybridization Diagn Mol Pathol 8 1999 47 53
40. D.T. Starczynowski, S. Vercauteren, A. Telenius, S. Sung, K. Tohyama, A. Brooks-Wilson, J.J. Spinelli, C.J. Eaves, A.C. Eaves, D.E. Horsman, W.L. Lam, and A. Karsan High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival Blood 112 2008 3412 3424
41. A. Thiel, M. Beier, D. Ingenhag, K. Servan, M. Hein, V. Moeller, B. Betz, B. Hildebrandt, C. Evers, U. Germing, and B. Royer-Pokora Comprehensive array CGH of normal karyotype myelodysplastic syndromes reveals hidden recurrent and individual genomic copy number alterations with prognostic relevance Leukemia 25 2011 387 399
42. K.A. Kolquist, R.A. Schultz, A. Furrow, T.C. Brown, J.Y. Han, L.J. Campbell, M. Wall, M.L. Slovak, L.G. Shaffer, and B.C. Ballif Microarray-based comparative genomic hybridization of cancer targets reveals novel, recurrent genetic aberrations in the myelodysplastic syndromes Cancer Genet 204 2011 603 628
43. A. Mohamedali, J. Gäken, N.A. Twine, W. Ingram, N. Westwood, N.C. Lea, J. Hayden, N. Donaldson, C. Aul, N. Gattermann, A. Giagounidis, U. Germing, A.F. List, and G.J. Mufti Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes Blood 110 2007 3365 3373
44. R.V. Tiu, L.P. Gondek, C.L. O'Keefe, P. Elson, J. Huh, A. Mohamedali, A. Kulasekararaj, A.S. Advani, R. Paquette, A.F. List, M.A. Sekeres, M.A. McDevitt, G.J. Mufti, and J.P. Maciejewski Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies Blood 117 2011 4552 4560
45. M.G. Afable 2nd, M. Wlodarski, H. Makishima, M. Shaik, M.A. Sekeres, R.V. Tiu, M. Kalaycio, C.L. O'Keefe, and J.P. Maciejewski SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes Blood 117 2011 6876 6884
46. R.R. Haraksingh, A. Abyzov, M. Gerstein, A.E. Urban, and M. Snyder Genome-wide mapping of copy number variation in humans: comparative analysis of high resolution array platforms PLoS One 6 2011 e27859
47. C. Curtis, A.G. Lynch, M.J. Dunning, I. Spiteri, J.C. Marioni, J. Hadfield, S.F. Chin, J.D. Brenton, S. Tavare, and C. Caldas The pitfalls of platform comparison: DNA copy number array technologies assessed BMC Genomics 10 2009 588
48. A.M. Mohamedali, H. Alkhatabi, A. Kulasekararaj, S. Shinde, S. Mian, F. Malik, A.E. Smith, J. Gäken, and G.J. Mufti Utility of peripheral blood for cytogenetic and mutation analysis in myelodysplastic syndrome Blood 122 2013 567 570
49. M.J. Walter, D. Shen, J. Shao, L. Ding, B.S. White, C. Kandoth, C.A. Miller, B. Niu, M.D. McLellan, N.D. Dees, R. Fulton, K. Elliot, S. Heath, M. Grillot, P. Westervelt, D.C. Link, J.F. DiPersio, E. Mardis, T.J. Ley, R.K. Wilson, and T.A. Graubert Clonal diversity of recurrently mutated genes in myelodysplastic syndromes Leukemia 27 2013 1275 1282
50. E. Papaemmanuil, M. Gerstung, L. Malcovati, S. Tauro, G. Gundem, P. Van Loo Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium Clinical and biological implications of driver mutations in myelodysplastic syndromes Blood 122 2013 3616 3627
51. A.H. Shih, S.S. Chung, E.K. Dolezal, S.J. Zhang, O.I. Abdel-Wahab, C.Y. Park, S.D. Nimer, R.L. Levine, and V.M. Klimek Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia Haematologica 98 2013 908 912
52. R.J. Gibbons, A. Pellagatti, D. Garrick, W.G. Wood, N. Malik, H. Ayyub, C. Langford, J. Boultwood, J.S. Wainscoat, and D.R. Higgs Identification of acquired somatic mutations in the gene encoding chromatin-remodeling factor ATRX in the alpha-thalassemia myelodysplasia syndrome (ATMDS) Nat Genet 34 2003 446 449
53. A. Bains, R. Luthra, L.J. Medeiros, and Z. Zuo FLT3 and NPM1 mutations in myelodysplastic syndromes: frequency and potential value for predicting progression to acute myeloid leukemia Am J Clin Pathol 135 2011 62 69
54. O. Kosmider, V. Gelsi-Boyer, L. Slama, F. Dreyfus, O. Beyne-Rauzy, B. Quesnel, M. Hunault-Berger, B. Slama, N. Vey, C. Lacombe, E. Solary, D. Birnbaum, O.A. Bernard, and M. Fontenay Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms Leukemia 24 2010 1094 1096
55. O. Fuchs, D. Provaznikova, M. Kocova, A. Kostecka, P. Cvekova, R. Neuwirtova, P. Kobylka, J. Cermak, J. Brezinova, J. Schwarz, J. Markova, P. Salaj, H. Klamova, J. Maaloufova, P. Lemez, L. Novakova, and K. Benesova CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma Blood Cells Mol Dis 40 2008 401 405
56. F. Dicker, C. Haferlach, J. Sundermann, N. Wendland, T. Weiss, W. Kern, T. Haferlach, and S. Schnittger Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML Leukemia 24 2010 1528 1532
57. M.L. Loh, S. Martinelli, V. Cordeddu, M.G. Reynolds, S. Vattikuti, C.M. Lee, M. Wulfert, U. Germing, P. Haas, C. Niemeyer, M.E. Beran, S. Strom, M. Lubbert, M. Sorcini, E.H. Estey, N. Gattermann, and M. Tartaglia Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia Leuk Res 29 2005 459 462
58. F. Thol, K.J. Suchanek, C. Koenecke, M. Stadler, U. Platzbecker, C. Thiede, T. Schroeder, G. Kobbe, S. Kade, P. Löffeld, S. Banihosseini, G. Bug, O. Ottmann, W.K. Hofmann, J. Krauter, N. Kröger, A. Ganser, and M. Heuser SETBP1 mutation analysis in 944 patients with MDS and AML Leukemia 27 2013 2072 2075
59. H. Makishima, K. Yoshida, N. Nguyen, B. Przychodzen, M. Sanada, Y. Okuno, K.P. Ng, K.O. Gudmundsson, B.A. Vishwakarma, A. Jerez, I. Gomez-Segui, M. Takahashi, Y. Shiraishi, Y. Nagata, K. Guinta, H. Mori, M.A. Sekeres, K. Chiba, H. Tanaka, H. Muramatsu, H. Sakaguchi, R.L. Paquette, M.A. McDevitt, S. Kojima, Y. Saunthararajah, S. Miyano, L.Y. Shih, Y. Du, S. Ogawa, and J.P. Maciejewski Somatic SETBP1 mutations in myeloid malignancies Nat Genet 45 2013 942 946
60. F. Lorenzo, K. Nishii, F. Monma, S. Kuwagata, E. Usui, and H. Shiku Mutational analysis of the KIT gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia Leuk Res 30 2006 1235 1239
61. R. Bejar, K. Stevenson, O. Abdel-Wahab, N. Galili, B. Nilsson, G. Garcia-Manero, H. Kantarjian, A. Raza, R.L. Levine, D. Neuberg, and B.L. Ebert Clinical effect of point mutations in myelodysplastic syndromes N Engl J Med 364 2011 2496 2506
62. K. Yoshida, M. Sanada, Y. Shiraishi, D. Nowak, Y. Nagata, R. Yamamoto, Y. Sato, A. Sato-Otsubo, A. Kon, M. Nagasaki, G. Chalkidis, Y. Suzuki, M. Shiosaka, R. Kawahata, T. Yamaguchi, M. Otsu, N. Obara, M. Sakata-Yanagimoto, K. Ishiyama, H. Mori, F. Nolte, W.K. Hofmann, S. Miyawaki, S. Sugano, C. Haferlach, H.P. Koeffler, L.Y. Shih, T. Haferlach, S. Chiba, H. Nakauchi, S. Miyano, and S. Ogawa Frequent pathway mutations of splicing machinery in myelodysplasia Nature 478 2011 64 69
63. T.A. Graubert, D. Shen, L. Ding, T. Okeyo-Owuor, C.L. Lunn, J. Shao, K. Krysiak, C.C. Harris, D.C. Koboldt, D.E. Larson, M.D. McLellan, D.J. Dooling, R.M. Abbott, R.S. Fulton, H. Schmidt, J. Kalicki-Veizer, M. O'Laughlin, M. Grillot, J. Baty, S. Heath, J.L. Frater, T. Nasim, D.C. Link, M.H. Tomasson, P. Westervelt, J.F. DiPersio, E.R. Mardis, T.J. Ley, R.K. Wilson, and M.J. Walter Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes Nat Genet 44 2011 53 57
64. F. Thol, S. Kade, C. Schlarmann, P. Löffeld, M. Morgan, J. Krauter, M.W. Wlodarski, B. Kölking, M. Wichmann, K. Görlich, G. Göhring, G. Bug, O. Ottmann, C.M. Niemeyer, W.K. Hofmann, B. Schlegelberger, A. Ganser, and M. Heuser Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes Blood 119 2012 3578 3584
65. E. Papaemmanuil, M. Cazzola, J. Boultwood, L. Malcovati, P. Vyas, D. Bowen Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts N Engl J Med 365 2011 1384 1395
66. L. Malcovati, E. Papaemmanuil, D.T. Bowen, J. Boultwood, M.G. Della Porta, C. Pascutto, E. Travaglino, M.J. Groves, A.L. Godfrey, I. Ambaglio, A. Galli, M.C. Da Via, S. Conte, S. Tauro, N. Keenan, A. Hyslop, J. Hinton, L.J. Mudie, J.S. Wainscoat, P.A. Futreal, M.R. Stratton, P.J. Campbell, E. Hellstrom-Lindberg, and M. Cazzola Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms Blood 118 2011 6239 6246
67. V. Visconte, H.J. Rogers, J. Singh, J. Barnard, M. Bupathi, F. Traina, J. McMahon, H. Makishima, H. Szpurka, A. Jankowska, A. Jerez, M.A. Sekeres, Y. Saunthararajah, A.S. Advani, E. Copelan, H. Koseki, K. Isono, R.A. Padgett, S. Osman, K. Koide, C. O'Keefe, J.P. Maciejewski, and R.V. Tiu SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes Blood 120 2012 3173 3186
68. M. Nikpour, A. Pellagatti, A. Liu, M. Karimi, L. Malcovati, V. Gogvadze, A.M. Forsblom, J.S. Wainscoat, M. Cazzola, B. Zhivotovsky, A. Grandien, J. Boultwood, and E. Hellström-Lindberg Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF Br J Haematol 149 2010 844 854
69. M. Wulfert, A.C. Küpper, C. Tapprich, S.S. Bottomley, D. Bowen, U. Germing, R. Haas, and N. Gattermann Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes Exp Hematol 36 2008 577 586
70. Y. Jiang, A. Dunbar, L.P. Gondek, S. Mohan, M. Rataul, C. O'Keefe, M. Sekeres, Y. Saunthararajah, and J.P. Maciejewski Aberrant DNA methylation is a dominant mechanism in MDS progression to AML Blood 113 2009 1315 1325
71. M.E. Figueroa, L. Skrabanek, Y. Li, A. Jiemjit, T.E. Fandy, E. Paietta, H. Fernandez, M.S. Tallman, J.M. Greally, H. Carraway, J.D. Licht, S.D. Gore, and A. Melnick MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation Blood 114 2009 3448 3458
72. A.H. Shih, O. Abdel-Wahab, J.P. Patel, and R.L. Levine The role of mutations in epigenetic regulators in myeloid malignancies Nat Rev Cancer 12 2012 599 612
73. M.J. Walter, L. Ding, D. Shen, J. Shao, M. Grillot, M. McLellan, R. Fulton, H. Schmidt, J. Kalicki-Veizer, M. O'Laughlin, C. Kandoth, J. Baty, P. Westervelt, J.F. DiPersio, E.R. Mardis, R.K. Wilson, T.J. Ley, and T.A. Graubert Recurrent DNMT3A mutations in patients with myelodysplastic syndromes Leukemia 25 2011 1153 1158
74. L. Shen, H. Kantarjian, Y. Guo, E. Lin, J. Shan, X. Huang, D. Berry, S. Ahmed, W. Zhu, S. Pierce, Y. Kondo, Y. Oki, J. Jelinek, H. Saba, E. Estey, and J.P. Issa DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes [Erratum appeared in J Clin Oncol 2010, 28:3098] J Clin Oncol 28 2010 605 613
75. K. Gronbaek, C. Muller-Tidow, G. Perini, S. Lehmann, M. Bach Treppendahl, K. Mills, C. Plass, B. Schlegelberger European Genomics and Epigenomics Study on MDS and AML (EuGESMA), COST Action BM0801 A critical appraisal of tools available for monitoring epigenetic changes in clinical samples from patients with myeloid malignancies Haematologica 97 2012 1380 1388
76. Z. Zuo, G.A. Calin, H.M. de Paula, L.J. Medeiros, M.H. Fernandez, M. Shimizu, G. Garcia-Manero, and C.E. Bueso-Ramos Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome Blood 118 2011 413 415
77. G.W. Rhyasen, and D.T. Starczynowski Deregulation of microRNAs in myelodysplastic syndrome Leukemia 26 2012 13 22
78. M.H. Raaijmakers, S. Mukherjee, S. Guo, S. Zhang, T. Kobayashi, J.A. Schoonmaker, B.L. Ebert, F. Al-Shahrour, R.P. Hasserjian, E.O. Scadden, Z. Aung, M. Matza, M. Merkenschlager, C. Lin, J.M. Rommens, and D.T. Scadden Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia Nature 464 2010 852 857
79. A. Raza, J.A. Reeves, E.J. Feldman, G.W. Dewald, J.M. Bennett, H.J. Deeg, L. Dreisbach, C.A. Schiffer, R.M. Stone, P.L. Greenberg, P.T. Curtin, V.M. Klimek, J.M. Shammo, D. Thomas, R.D. Knight, M. Schmidt, K. Wride, J.B. Zeldis, and A.F. List Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q Blood 111 2008 86 93
80. R. Itzykson, O. Kosmider, T. Cluzeau, V. Mansat-De Mas, F. Dreyfus, O. Beyne-Rauzy, B. Quesnel, N. Vey, V. Gelsi-Boyer, S. Raynaud, C. Preudhomme, L. Ades, P. Fenaux, M. Fontenay Groupe Francophone des Myélodysplasies (GFM) Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias Leukemia 25 2011 1147 1152
81. R. Garzon, S. Liu, M. Fabbri, Z. Liu, C.E. Heaphy, E. Callegari, S. Schwind, J. Pang, J. Yu, N. Muthusamy, V. Havelange, S. Volinia, W. Blum, L.J. Rush, D. Perrotti, M. Andreeff, C.D. Bloomfield, J.C. Byrd, K. Chan, L.C. Wu, C.M. Croce, and G. Marcucci MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1 Blood 113 2009 6411 6418
82. H. Yang, Z. Fang, Y. Wei, Y. Hu, G.A. Calin, H.M. Kantarjian, and G. Garcia-Manero Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA Am J Hematol 86 2011 237 238
83. M.Y. Follo, C. Finelli, S. Mongiorgi, C. Clissa, C. Bosi, N. Testoni, F. Chiarini, G. Ramazzotti, M. Baccarani, A.M. Martelli, L. Manzoli, G. Martinelli, and L. Cocco Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS Proc Natl Acad Sci USA 106 2009 16811 16816
84. P.L. Greenberg, E. Attar, J.M. Bennett, C.D. Bloomfield, U. Borate, C.M. De Castro, H.J. Deeg, O. Frankfurt, K. Gaensler, G. Garcia-Manero, S.D. Gore, D. Head, R. Komrokji, L.J. Maness, M. Millenson, M.R. O'Donnell, P.J. Shami, B.L. Stein, R.M. Stone, J.E. Thompson, P. Westervelt, B. Wheeler, D.A. Shead, and M. Naganuma Myelodysplastic syndromes: clinical practice guidelines in oncology J Natl Compr Canc Netw 11 2013 838 874